公开(公告)号：US20210363254A1

公开(公告)日：2021-11-25

申请号：US16981828

申请日：2019-03-18

Applicant: Novartis AG

Inventor： Stephane FERRETTI ,  Nelson GUERREIRO ,  Ensar HALILOVIC ,  Sebastien JEAY ,  Astrid JULLION ,  Jinsheng LIANG ,  Christophe MEILLE ,  Hui-Qin WANG ,  Jens WUERTHNER

IPC: C07K16/28 ,  A61P35/00 ,  C07D487/04

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) a HDM2-p53 interaction inhibitor, said combination for simultaneous, separate or sequential administration for use in the treatment of a proliferative disease, a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination; said proliferative disease being a TP53 wildtype tumor, in particular TP53 wildtype renal cell carcinoma (RCC) or TP53 wildtype colorectal cancer (CRC).

公开(公告)号：US20210386763A1

公开(公告)日：2021-12-16

申请号：US17415985

申请日：2019-12-18

Applicant: NOVARTIS AG

Inventor： Nelson GUERREIRO ,  Ensar HALILOVIC ,  Astrid JULLION ,  Christophe MEILLE ,  Youzhen WANG

IPC: A61K31/635 ,  A61K31/506 ,  A61K45/06 ,  A61P35/02

Abstract: The present invention relates to the combination of the HDM2-p53 interaction inhibitor drug (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one [HDM201] and the BCL2 inhibitor 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-4yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide [venetoclax]. The present invention further relates to the use of said combination in the treatment of cancer, in particular hematological tumors. The present invention further relates to dose and dosing regimen related to this combination cancer treatment.

公开(公告)号：US20250041296A1

公开(公告)日：2025-02-06

申请号：US17416008

申请日：2019-12-18

Applicant: NOVARTIS AG

Inventor： Nelson GUERREIRO ,  Astrid JULLION ,  Christophe MEILLE ,  Claire FABRE

IPC: A61K31/506 ,  A61K31/553 ,  A61K31/635 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/395

Abstract: The present invention relates to the HDM2-p53 interaction inhibitor (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one (HDM201) for use in the treatment of hematological tumors, wherein the drug is administered following an extended low dose regimen characterized by a higher dose during induction and a lower dose during consolidation.

公开(公告)号：US20220031697A1

公开(公告)日：2022-02-03

申请号：US17401600

申请日：2021-08-13

Applicant: Novartis AG

Inventor： Stephane FERRETTI ,  Nelson GUERREIRO ,  Sebastien JEAY ,  Astrid JULLION ,  Christophe MEILLE ,  Jens WUERTHNER ,  Claire Fabre

IPC: A61K31/506 ,  A61P35/00 ,  A61K31/553 ,  A61K31/706 ,  A61K31/7068 ,  A61K45/06

Abstract: The present invention relates to the HDM2-p53 interaction inhibitors (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one (HDM201), or a pharmaceutically acceptable non-covalent derivative thereof, for use in the treatment of patients with hematological tumors, wherein the drug is administered by an extended low dose dosing regimen.